Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

VIENNA, Oct. 21 /PRNewswire/ -- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

Intercell's vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients in a Phase II proof-of-concept trial. Nitazoxanide is an oral therapy that targets host cell factors involved in HCV replication and is not associated with viral mutations conferring resistance. Nitazoxanide has been shown to induce sustained virologic response as monotherapy in some patients chronically infected with HCV.

The planned European Phase II trial will include about 60 treatment-naïve patients chronically infected with HCV genotype-1 in three treatment arms: (1) IC41 plus nitazoxanide, (2) IC41 plus nitazoxanide and Pegasys® (peginterferon alfa-2a) and (3) Pegasys and Copegus® (ribavirin), the current standard of care, as an active control. The primary endpoint will be sustained virologic response (no detectable HCV RNA 24 weeks after end-of-treatment).

The companies involved in the combination study will retain commercial rights for their respective products.

"We are very pleased about this important next step in the development of our vaccine candidate against Hepatitis C. The distinctly different mode-of-action and the outstanding tolerability of both treatments create a joint approach in a field that will continue to have high unmet medical need over the next decades," stated Gerd Zettlmeissl, CEO of Intercell.

"We are excited about this novel therapeutic approach for chronic Hepatitis C," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "There is an important need for novel therapies that offer improvements in safety and efficacy com
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015   Proxsys Rx, ... (IOPP™) is expanding its population health management ... transition of care program for hospitals and ... provides hospitals with technology systems and pharmacy ... that have been mandated by Center for ...
(Date:8/27/2015)... Aug. 27, 2015   NineSigma the leading innovation ... $450M in estimated overall revenue growth and anticipates the creation ... Frontier Open Innovation Incentive (OII). In 2013, ... a grant of over $2 million to accelerate adoption of ... $10 Million and $1 Billion in revenues. To date over ...
(Date:8/27/2015)... August 27, 2015 According to ... by Type (Integrated, Standalone), by Deployment Mode (Web based, ... Emergency Healthcare Service Providers), by Component - Global Trends ... Market is estimated at $501.1 Million 2014, and is ... CAGR of 7.6% from 2014 to 2019. ...
Breaking Medicine Technology:Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 2State of Ohio and NineSigma Collaborate to Drive Regional Economic Growth and Job Creation 3Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
... , SANTA MONICA, Calif. and ... QUOSA, Inc., today announced that Cubist Pharmaceuticals ... between Reprints Desk,s STM Document Delivery service with QUOSA,s ... literature re-use. The integrated solution features integration with ...
... , SOUTH SAN FRANCISCO, Calif., Dec. 9 Anesiva, ... 3, 2009, Anesiva entered into an Asset Purchase Agreement which ... Technologies, Ltd., dated November 30, 2009, and sold certain assets ... British Virgin Island LLC, and Lee,s Pharmaceuticals (HK) Limited (Lee,s ...
Cached Medicine Technology:Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2
(Date:8/27/2015)... ... , ... Banc Intranets recently entered into a strategic partnership with ... City, Tenn.-based firms to work synergistically to promote similar products to the same market. ... organizations in the financial, commercial and services sectors. The software, which is sold by ...
(Date:8/27/2015)... ... 2015 , ... For the first time, Ninja® introduces Nutrient ... Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. These two exciting ... to a whole new level. This line of Nutri Ninja products is designed ...
(Date:8/27/2015)... Springs, FL (PRWEB) , ... August 27, 2015 , ... Florida Hospital North Pinellas, located ... Palm Harbor in the Fall of 2016. The new facility will be located at US ... , The property closed on August 18, and work on the project is slated ...
(Date:8/27/2015)... NY (PRWEB) , ... August 27, 2015 , ... King ... this August. Founded by Michael J. Cullen in 1930 and recognized by the ... forever. , Still family owned and operated, the Cullen & Kennedy families have ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch ... to having twelve offices in three counties, LA, Orange and San Bernardino. ... region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and ...
Breaking Medicine News(10 mins):Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2
...
... today announced that the U.S. Court of Appeals for ... reversal of the district court judgment in its ... ,On February 22, 2007, the district court for ... of Pfizer and Mylan immediately appealed and has continued ...
... WASHINGTON, "Prospective parents can take positive lifestyle steps to ... with a healthy heart," says the American Heart ... Council on Cardiovascular Disease in the Young and endorsed ... knowledge reflected in medical and scientific literature and identified ...
... of California scientists have found that cancer drug enhances ... ,A protein complex called chromatin causes ... shortens as it coils. When chromatin loosens, genes associated ... shown that the protein CBP causes chromatin to relax, ...
... in the June issue of the journal Cell Metabolism, published ... result in increased levels of a newly identified 'starvation ... show that the hormone plays a critical role in the ... and in those fed an Atkins-like diet. ,That ...
... studies on the cardiovascular effects of HRT, the level ... heart disease (CHD) remains controversial, according to BMJ ... an editorial published today, BMJ Clinical Evidence reports that ... reduces the risks of CHD, the Womens Health Initiative ...
Cached Medicine News:Health News:Women of Child-Bearing Age Urged to Take a Multivitamin With Folic Acid 2Health News:Cancer Drug Induces HDAC Inhibitor and Enhance Long-term Memory 2Health News:Effects of 'starvation Hormone'-Newly Identified in Low-carb Diets 2
... provides optimized balance of pulse strength, pulse ... cleaning in the O.R. Unlike disposable plastic ... forged in die-cast metal and powered by ... The result is unparalleled performance in cleaning, ...
Used for arthroscopic or open shoulder surgery. Powered positioning of back section inclines from 0 degrees to 90 degrees. Removable shoulder panels provide an eight-inch (203-mm) access area behind ...
... 1st MPJ IMPLANT SYSTEM is a unique ... of the 1st metatarsal phalangeal joint resulting ... revision of a previous arthroplasty. The ... pain relief, superior function and longevity. ...
... play an important part in our daily ... rheumatic changes can cause severe handicaps. A ... finger-joint prostheses was to produce a reconstructed ... function as nearly possible.,The cementless RM Finger ...
Medicine Products: